Development and validation of a nomogram for predicting cardiovascular mortality risk for diffuse large B-cell...

Area of Science:

• Oncology
• Cardiovascular Medicine
• Biostatistics

Background:

• Cardiovascular mortality (CVM) is a significant concern in diffuse large B-cell lymphoma (DLBCL) patients.
• Accurate prediction of CVM is crucial for optimizing treatment strategies and improving patient outcomes.

Purpose of the Study:

• To construct and validate a nomogram for predicting CVM in pediatric, adolescent, and adult DLBCL patients.
• To identify key risk factors associated with CVM in DLBCL.

Main Methods:

• Utilized the SEER database (2000-2019) for DLBCL patients with a single primary tumor.
• Employed competing risk models and cumulative incidence functions for CVM analysis.
• Randomly split data into training (70%) and validation (30%) cohorts for nomogram construction and assessment.

Main Results:

• Included 104,606 DLBCL patients; 5.02% experienced CVM.
• Developed a nomogram based on seven factors (age, gender, race, tumor grade, stage, radiation, chemotherapy) with excellent discrimination and calibration.
• Achieved high C-index and AUC values in both training and validation sets, indicating reliable prediction accuracy.

Conclusions:

• The developed nomogram provides a reliable tool for predicting CVM in DLBCL patients.
• This tool can assist clinicians in making informed treatment decisions at the time of diagnosis.
• The nomogram demonstrates excellent predictive performance and clinical utility.